Keyphrases
5-HT1A Agonist
12%
5-HT1A Receptor
12%
5-HT1B
12%
5-HT3 Antagonist
12%
Acute Treatment
12%
Antidepressants
12%
Clinical Levels
25%
Days of Treatment
25%
Depressed Patients
12%
Direct Modulation
25%
Female Rats
62%
High Dose
12%
Male Rat Sexual Behavior
12%
Male Rats
37%
Male Sexual Behavior
25%
Minimal Impact
12%
Multimodal Antidepressants
12%
Non-treatment
12%
Occupancy
12%
Ondansetron
25%
Paroxetine
25%
Patient Compliance
12%
Proceptive Behavior
25%
Receptor Modulation
100%
Receptor Occupancy
12%
Repeated Administration
37%
Repeated Treatment
12%
Selective Ligands
12%
Selective Serotonin Reuptake Inhibitors
12%
Serotonergic
12%
Serotonin Receptors
12%
Serotonin Transporter
12%
Sex Effect
100%
Sexual Behavior
100%
Sexual Dysfunction
12%
Sexual Side Effects
25%
Time Effect
100%
Time Study
100%
Treatment Cessation
12%
Treatment-related
12%
Vortioxetine
100%
Neuroscience
5-HT Receptor
12%
5-HT1A Agonists
12%
5-HT1A Receptor
12%
5-HT1B Agonists
12%
5-HT3 Antagonist
12%
Antidepressant
25%
Behavior (Neuroscience)
25%
Female Rats
62%
Flesinoxan
37%
Ondansetron
25%
Paroxetine
25%
Receptor
12%
Receptor Modulation
100%
Receptor Occupancy
12%
Selective Serotonin Reuptake Inhibitor
12%
Serotonergic
12%
Serotonin Transporter
12%
Sexual Behavior
100%
Vortioxetine
100%
Pharmacology, Toxicology and Pharmaceutical Science
Antidepressant
25%
Clinical Study
12%
Flesinoxan
37%
Paroxetine
25%
Receptor
100%
Selective Serotonin Reuptake Inhibitor
12%
Serotonin 1A Agonist
12%
Serotonin 1B Agonist
12%
Serotonin 3 Antagonist
12%
Serotonin Receptor
12%
Serotonin Transporter
12%
Side Effect
37%
Vortioxetine
100%
Zofran
25%